Amino acids as Co-amorphous excipients for simvastatin and glibenclamide: Physical properties and stability

Molecular Pharmaceutics

Volumn 11, Issue 7, 2014, Pages 2381-2389

  Laitinen, Riikka ^a   Löbmann, Korbinian ^b   Grohganz, Holger ^b   Strachan, Clare ^c   Rades, Thomas ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

amino acid; amorphous; co amorphous; stability; tautomerism

Indexed keywords

ASPARTIC ACID; EXCIPIENT; GLIBENCLAMIDE; LYSINE; SERINE; SIMVASTATIN; THREONINE; AMINO ACID; POLYMER;

ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; INFRARED SPECTROSCOPY; MELTING POINT; PHASE TRANSITION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RECEPTOR BINDING; SOLID STATE; TAUTOMER; X RAY POWDER DIFFRACTION; CHEMISTRY; MEDICINAL CHEMISTRY; POWDER DIFFRACTION; PROCEDURES; SOLUBILITY; X RAY DIFFRACTION;

AMINO ACIDS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; EXCIPIENTS; GLYBURIDE; POLYMERS; POWDER DIFFRACTION; SIMVASTATIN; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 84903989949     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500107s     Document Type: Article

References (49)

1. Williams, H. D.; Trevaskis, N. L.; Charman, S. A.; Shanker, R. M.; Charman, W. N.; Pouton, C. W.; Porter, C. J. H. Strategies to address low drug solubility in discovery and development Pharmacol. Rev. 2013, 65, 315-499
2. Xu, W.; Riikonen, J.; Lehto, V. P. Mesoporous systems for poorly soluble drugs Int. J. Pharm. 2013, 453, 181-197
3. Brough, C.; Williams, R. O., III Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery Int. J. Pharm. 2013, 453, 157-166
4. Vo, C. L.; Park, C.; Lee, B. Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs Eur. J. Pharm. Biopharm 2013, 85, 799-813
5. Alam, M. A.; Al-Jenoobi, F. I.; Al-mohizea, A. M. Commercially bioavailable proprietary technologies and their marketed products Drug Discovery Today 2013, 18, 936-949
6. Kaushal, A. M.; Gupta, P.; Bansal, A. K. Amorphous drug delivery systems: molecular aspects, design and performance Crit. Rev. Ther. Drug Carrier Syst. 2004, 21, 133-193
7. Yu, L. Amorphous pharmaceutical solids; preparation, characterization and stabilization Adv. Drug. Delivery Rev. 2001, 48, 27-42
8. Zhang, G. G. Z; Law, D.; Scmitt, E. A.; Qiu, Y. Phase transformation considerations during process development and manufacture of solid oral dosage forms Adv. Drug Delivery Rev. 2004, 56, 371-390
9. Aaltonen, J.; Rades, T. Towards physico-relevant dissolution testing: the importance of solid-state analysis in dissolution Dissolution Technol. 2009, 16, 47-54
10. Zheng, E.; Jain, A.; Papoutsakis, D.; Dannenfelser, R. M.; Panicucci, R.; Garad, S. Selection of oral bioavailability enhancing formulations during drug discovery Drug Dev. Ind. Pharm. 2012, 38, 235-47
11. Janssens, S.; Van den Mooter, G. Review: physical chemistry of solid dispersions J. Pharm. Pharmacol. 2009, 61, 1571-1586
12. Vasconcelos, T.; Sarmento, B.; Costa, P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs Drug Discovery Today 2007, 12, 1068-1075
13. Qian, F.; Huang, J.; Hussain, M. A. Drug-polymer solubility and miscibility: stability consideration and practical challenges in amorphous solid dispersion development J. Pharm. Sci. 2010, 99, 2941-2947
14. Srinarong, P.; de Waard, H.; Frijlink, H. W.; Hinrichs, W. L. J. Improved dissolution behavior of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations Expert Opin. Drug Delivery 2011, 8, 1121-1140
15. Allesø, M.; Chieng, N.; Rehder, S.; Rantanen, J.; Rades, T.; Aaltonen, J. Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: amorphous naproxen-cimetidine mixtures prepared by mechanical activation J. Controlled Release 2009, 136, 45-53
16. Chieng, N.; Aaltonen, J.; Saville, D.; Rades, T. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation Eur. J. Pharm. Biopharm. 2009, 71, 47-54
17. Löbmann, K.; Laitinen, R.; Grohganz, H.; Gordon, K. C.; Strachan, C.; Rades, T. Co-amorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen Mol. Pharm. 2011, 8, 1919-1928
18. Löbmann, K.; Strachan, C.; Grohganz, H.; Rades, T.; Korhonen, O.; Laitinen, R. Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions Eur. J. Pharm. Biopharm. 2012, 81, 159-169
19. Löbmann, K.; Laitinen, R.; Grohganz, H.; Strachan, C.; Rades, T.; Gordon, K. C. A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin Int. J. Pharm. 2013, 453, 80-87
20. Löbmann, K.; Grohganz, H.; Laitinen, R.; Strachan, C.; Rades, T. Amino acids as co-amorphous stabilizers for poorly water soluble drugs-Part 1: preparation, stability and dissolution enhancement Eur. J. Pharm. Biopharm. 2013, 85, 873-881
21. Löbmann, K.; Laitinen, R.; Grohganz, H.; Rades, T.; Grohganz, H. Amino acids as co-amorphous stabilizers for poorly water-soluble drugs-Part 2: molecular interactions Eur. J. Pharm. Biopharm. 2013, 85, 882-888
22. Istvan, E. Statin inhibition of HMG-CoA reductase: a 3-dimensional view Atheroscler. Suppl. 2003, 4, 3-8
23. Winkler, M.; Stephan, D.; Bieger, S.; Kühner, P.; Wolff, F.; Quast, U. Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands J. Pharmacol. Experim. Ther. 2007, 322, 701-708
24. Istvan, E. S.; Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase Science 2001, 292, 1160-1164
25. Mikhailov, M. V.; Mikhailova, E. A.; Ashcroft, S. J. H. Molecular structure of the glibenclamide binding site of the L-cell KATP channel FEBS Lett. 2001, 499, 154-160
26. Gordon, M.; Taylor, J. S. Ideal copolymers and the second order transition of synthetic rubbers 1. Non-crystalline co-polymers J. Appl. Chem. 1952, 26, 493-500
27. Mattern, M.; Winter, G.; Kohnert, U.; Lee, G. Formulation of proteins in vacuum-dried glasses. II. Process and storage stability in sugar-free amino acid systems Pharm. Dev. Technol. 1999, 4, 199-208
28. Clarkes Analysis of Drugs and Poisons; Moffat, A. C.; Osselton, M. D.; Widdop, B.; Watts, J., Eds.; Pharmaceutical Press: London, 2011.
29. Berlin, E.; Pallansch, M. J. Densities of several proteins and l -amino acids in the dry state J. Phys. Chem. 1968, 72, 1887-1889
30. Patterson, J. E.; James, M. B.; Forster, A. H.; Lancaster, R. W.; Butler, J. M.; Rades, T. The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds J. Pharm. Sci. 2005, 94, 1998-2012
31. Marsac, P. J.; Li, T.; Taylor, L. S. Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters Pharm. Res. 2009, 26, 139-151
32. Marsac, P. J.; Konno, H.; Taylor, L. S. A comparison of the physical stability of amorphous felodipine and nifedipine systems Pharm. Res. 2006, 23, 2306-2316
33. Nair, R.; Nyamweya, N.; Gönen, S.; Martinez-Miranda, L. J.; Hoag, S. W. Influence of various drugs on the glass transition temperature of poly(vinylpyrrolidone): a thermodynamic and spectroscopic investigation Int. J. Pharm. 2001, 225, 83-96
34. Gupta, P.; Thilaqavathi, R.; Chakraborti, A. K.; Bansal, A. K. Role of molecular interaction in stability of celecoxib-PVP amorphous systems Mol. Pharmaceutics 2005, 2, 384-391
35. Shamblin, S. L.; Huang, E. Y.; Zografi, G. The effects of colyophilized polymeric additives on the glass transition temperature and crystallization of amorphous sucrose J. Therm. Anal. Calorim. 1996, 47, 1567-1579
36. Taylor, L. S.; Zografi, G. Sugar-polymer hydrogen bond interactions in lyophilized amorphous mixtures J. Pharm. Sci. 1998, 87, 1615-1621
37. Shamblin, S. L.; Taylor, L. S.; Zografi, G. Mixing behavior of colyophilized binary systems J. Pharm. Sci. 1998, 87, 694-701
38. Kulthe, V. V.; Chaudhari, P. D.; Aboul-Enein, H. Y. Freeze-dried amorphous dispersions for solubility enhancement of thermosensitive API having low molecular lipophilicity Drug. Res. (Stuttg) [Online early access]. DOI: 10.1055/s-0033-1363249. Published Online: Jan 17, 2014.
39. Kaminska, E.; Adrjanowicz, K.; Kaminski, K.; Wlodarczyk, P.; Hawelek, L.; Kolodziejczyk, K.; Tarmacka, M.; Zakowiecki, D.; Kacmarcyk-Sedlak, I.; Pilch, J.; Paluch, M. A new way of stabilization of furosemide upon cryogenic ginding by using acylated saccharides matrices. The role of hydrogen bonds in decomposition mechanism Mol. Pharmacol. 2013, 10, 1824-1835
40. Grzybowska, K.; Paluch, M.; Wlodarczyk, P.; Kaminski, K.; Hawelek, L. Enhancement of amorphous celecoxib stability by mixing it with octaacetylmaltose: the molecular dynamics study Mol. Pharm. 2012, 9, 894-904
41. Rehder, S.; Sakmann, A.; Rades, T.; Leopold, C. S. Thermal degradation of amorphous glibenclamide Eur. J. Pharm. Biopharm. 2012, 80, 203-208
42. Wojnarowska, Z.; Grzybowska, K.; Adrjanowicz, K.; Kaminski, K.; Paluch, M.; Hawelek, L.; Wrzalik, R.; Dulski, M. Study of the amorphous glibenclamide drug: analysis of the molecular dynamics of quenched and cryomilled material Mol. Pharmaceutics 2010, 7, 1692-1707
43. Heinz, A.; Strachan, C. J.; Gordon, K. C.; Rades, T. Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy J. Pharm. Pharmacol. 2009, 61, 971-988
44. Barth, A. The infrared absorption of amino acid side chains Prog. Biophys. Mol. Biol. 2000, 74, 141-173
45. Rozenberg, M.; Shoham, G. FTIR spectra of solid poly- l -lysine in the stretching NH mode range Biophys. Chem. 2007, 125, 166-171
46. Hassan, M. A.; Najib, N. M.; Suleiman, M. S. Characterization of glibenclamide glassy state Int. J. Pharm. 1991, 67, 131-137
47. Panagopoulou-Kaplani, A.; Malamataris, S. Preparation and characterisation of a new insoluble polymorphic form of glibenclamide Int. J. Pharm. 2000, 195, 239-246
48. Zhou, Y.; Roos, Y. H. Stability and plasticizing and crystallization effects of vitamins in amorphous sugar systems J. Agric. Food Chem. 2012, 60, 1075-1083
49. V600E kinase inhibitors by computational explorations Chem. Biol. Drug Des. 2014, 83, 643-655